Johnson & Johnson's investigational co-antibody therapy JNJ-4804 demonstrated higher clinical remission and endoscopic response rates compared to golimumab and guselkumab in patients with moderately to severely active ulcerative colitis and Crohn's disease who failed two or more systemic therapies. Data from Phase 2b DUET studies showed meaningful improvements at Week 48, especially in highly refractory patients, addressing a critical unmet need in inflammatory bowel disease treatment. JNJ-4804 targets both IL-23 and TNF pathways, offering a synergistic approach. Based on these results, Johnson & Johnson plans to initiate Phase 3 trials for both conditions.
Johnson & Johnson announced that the Phase 3 MonumenTAL-3 study demonstrated that TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, significantly improved progression-free survival (up to 81.3%) and overall survival (up to...
A recent study by Spherix Global Insights highlights the unmet need for new treatments in warm autoimmune hemolytic anemia (w-AIHA), especially beyond second-line therapies where no clear standard exists. Current treatments rely heavily on corticoste...
Johnson & Johnson announced that its drug IMAAVY (nipocalimab-aahu) achieved a significant and durable hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA) during a Phase 2/3 trial. Patients receiving the 30 mg/kg dose showed...
Johnson & Johnson continues to attract investors with its leaner business model focused on innovative medicine and medical technology after spinning off Kenvue. The company raised its dividend by 3.1%, marking 64 years of consecutive growth, supporte...
